Beyond checkpoint suppression, functional assays demonstrated that PD-L1 silencing using BMV-VLPs restored T-cell cytotoxicity in melanoma cells, sensitized a secondary tumor model (CMT64-OVA) to antigen-specific killing, and enhanced allogeneic T-cell proliferation in a mixed leukocyte reaction. Here, CD274 is linked to melanoma.